India, July 1 -- Today's leading biotech gainers include Can-Fite, following an update from its pancreatic cancer study; SeaStar Medical, driven by improving quarter-over-quarter revenue for its flagship product; and Elicio, which has refined its Phase 3 development strategy for ELI-002, among others.
Read on.
Can-Fite Climbs on Pancreatic Cancer Data
Can-Fite BioPharma Ltd. (CANF) soared more than 55% on Wednesday, following an update on its Phase 2a pancreatic cancer study with Namodenoson.
The company's Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma met its primary safety endpoint and demonstrated durable overall survival outcomes. Based on the trial findings, the company plans to adv...